Loading...
01/11 03:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed significant challenges, including a revenue decline due to TRICARE payment suspension, increased competition, and regulatory hurdles. Despite cost-saving measures and long-term growth optimism, the lack of guidance for 2025, expected net loss, and unclear TRICARE resolution weigh negatively. The Q&A section underscored uncertainties, particularly around TRICARE payments, which are crucial for revenue recovery. The absence of clear management responses further adds to investor concerns. Given these factors, a negative stock price reaction is expected over the next two weeks.
Net Revenue $26,600,000 (down from $46,500,000 in Q1 2024), primarily due to a temporary payment suspension from TRICARE and slowing order growth.
Device Revenue $11,900,000, part of the overall revenue decline attributed to TRICARE's payment suspension.
Supplies Revenue $14,700,000, also affected by the TRICARE payment suspension.
Gross Profit $18,200,000 (69% of revenue), down from $37,200,000 (80% of revenue in Q1 2024), due to lower revenue.
Sales and Marketing Expenses $16,900,000 (decreased by 28% from the previous year), primarily due to headcount reduction.
G&A Expenses $14,400,000, up from $13,300,000 last year.
Net Loss $10,400,000 ($0.33 per share), compared to a net income of $10,000 last year.
Adjusted EBITDA Loss of $11,800,000, compared to an adjusted EBITDA of $1,700,000 in Q1 2024.
Working Capital $40,000,000, indicating a strong balance sheet.
Cash on Hand Approximately $24,000,000.
Annual Savings from Staff Reduction Approximately $35,000,000, due to a 15% decrease in overall staff.
NICO Pulse Oximeter: The NICO pulse oximeter has completed all EMC and safety tests and is set for FDA submission, expected in May 2025. This product aims to provide accurate readings across all skin types and improve health equity.
TRICARE Payment Suspension: TRICARE has placed a temporary payment suspension while reviewing compliance with their policies. A response is expected by June 9, 2025.
New Revenue Opportunities: Zynex is focusing on diversifying revenue streams, including personal injury claims and promoting bracing products to prescribers.
Staff Reduction: In March 2025, Zynex reduced overall staff by approximately 15%, primarily in the corporate office, anticipating annual savings of about $35 million.
Sales Force Restructuring: The sales force is being refocused on new revenue opportunities, with a goal to improve productivity and drive growth.
Business Restructuring: Zynex is restructuring to operate without TRICARE business in a worst-case scenario, trimming unproductive areas to return to growth.
Long-term Revenue Goals: The company aims to generate revenue exceeding $800 million annually, with a focus on both pain management and patient monitoring divisions.
TRICARE Payment Suspension: TRICARE has placed a temporary payment suspension while reviewing compliance with their policies, impacting revenue significantly. The company is awaiting a response by June 9, which could restore payments.
Regulatory Challenges: The company is navigating regulatory challenges related to TRICARE and is preparing for FDA submission of the NICO pulse oximeter, which could face delays.
Staff Reductions: A 15% reduction in overall staff has been implemented to cut costs, which may affect operational capacity and morale.
Revenue Decline: Net revenue dropped to $26.6 million from $46.5 million year-over-year, primarily due to the TRICARE payment suspension and reduced sales rep productivity.
Market Competition: The company faces competitive pressures in the medical device market, particularly with the introduction of the NICO pulse oximeter, which aims to address biases in current technology.
Economic Factors: The overall economic environment and reimbursement changes are sensitive factors that could impact revenue recognition and operational performance.
Future Revenue Uncertainty: There is uncertainty regarding future revenue streams, especially if TRICARE payments do not resume, necessitating a restructuring of the business model.
TRICARE Payment Suspension: Zynex is currently facing a temporary payment suspension from TRICARE while they review compliance with their billing practices. The company is restructuring to operate without TRICARE revenue in a worst-case scenario.
Cost Containment: Zynex has reduced overall staff by approximately 15%, primarily in the corporate office, which is expected to result in annual savings of approximately $35 million.
NICO Pulse Oximeter: Zynex is preparing to submit the NICO pulse oximeter for FDA approval, which is expected to be filed shortly. This product aims to provide accurate readings across all skin types and is anticipated to launch in 2026.
Sales Force Refocus: The company is refocusing its sales force on new revenue opportunities to drive growth, even without TRICARE patients.
Q2 Revenue Guidance: For Q2 2025, Zynex estimates revenue to be approximately $27 million, with an expected loss of $0.20 per share.
Long-term Revenue Goal: Zynex aims to generate revenue exceeding $800 million annually in the long term.
2025 Revenue Expectations: The company has not provided specific guidance for 2025 but is optimistic about growth opportunities beyond TRICARE.
Annual Savings from Staff Reduction: $35,000,000
Estimated Revenue for Q2 2025: $27,000,000
Expected EPS for Q2 2025: Loss of $0.20 per share
Net Revenue for Q1 2025: $26,600,000
Net Loss for Q1 2025: $10,400,000 or $0.33 per share
Cash on Hand: $24,000,000
Working Capital: $40,000,000
The earnings call reveals significant financial challenges, including a drastic revenue decline, negative cash flow, and asset impairment. Despite efforts to stabilize, uncertainties from government investigations and debt obligations overshadow potential positive developments. The suspension of guidance and liquidity concerns further exacerbate the situation. With no clear resolution in sight and ongoing operational challenges, the stock is likely to experience a strong negative reaction in the short term.
The earnings call reveals significant challenges: a sharp revenue decline, ongoing FDA approval delays, and unresolved TRICARE payment issues. The restructuring efforts, while aimed at cost savings, are causing short-term disruptions. Despite a strong balance sheet, the net loss and declining gross profit raise concerns. Management's unclear responses on key issues further contribute to a negative sentiment. With a mid-cap stock, these factors likely result in a negative market reaction, estimated between -2% to -8%.
The earnings call revealed significant challenges, including a revenue decline due to TRICARE payment suspension, increased competition, and regulatory hurdles. Despite cost-saving measures and long-term growth optimism, the lack of guidance for 2025, expected net loss, and unclear TRICARE resolution weigh negatively. The Q&A section underscored uncertainties, particularly around TRICARE payments, which are crucial for revenue recovery. The absence of clear management responses further adds to investor concerns. Given these factors, a negative stock price reaction is expected over the next two weeks.
The earnings call highlights significant challenges: a 43% revenue decline, regulatory issues with TriCare, and operational inefficiencies. The lack of guidance and unclear management responses further exacerbate concerns. Although cost-saving measures and potential new product launches provide some optimism, the immediate outlook remains negative due to the unresolved TriCare suspension and expected net losses. The sentiment in the Q&A indicates uncertainty and skepticism among analysts, leading to a negative stock price prediction in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
